Biblio

Found 4 results
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Li, D  [Clear All Filters]
2011
Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet [Internet]. 2011;378:1779-1787. Available from: http://www.hubmed.org/display.cgi?uids=22047971
2010
Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry [Internet]. 2010. Available from: http://www.hubmed.org/display.cgi?uids=20562430
2009
Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study, et al. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther [Internet]. 2009;31:1724-1736. Available from: http://www.hubmed.org/display.cgi?uids=19808131
2007
Shi Y, Feng Y, Kang J, Liu C, Li Z, Li D, Cao W, Qiu J, Guo Z, Bi E, et al. Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin 1. Nat Immunol [Internet]. 2007;8:817-824. Available from: http://www.hubmed.org/display.cgi?uids=17618287